Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.

Tropical gastroenterology : official journal of the Digestive Diseases Foundation - 1 Jan 2000

Butt Amna Subhan, Mumtaz Khalid, Aqeel Irum, Shah Hasnain A, Hamid Saeed, Jafri Wasim

Abstract excerpt

BACKGROUND: Chronic hepatitis C (CHC) virus infection in patients with cirrhosis is difficult to treat. There is limited data on the outcome of treatment for genotype 3 HCV infection with cirrhosis. AIMS: To determine sustained virological response (SVR) and its predictive factors in patients with cirrhosis due to genotype 3 HCV infection treated with pegylated interferon and ribavirin (RBV). METHODS: Consecutive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Logistic Models

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 20426280

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.PMID 20426280Read ↗

Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients.Semantic proximity Read ↗

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.Semantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.Semantic proximity Read ↗

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.Semantic proximity Read ↗

High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia.Semantic proximity Read ↗

Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.Semantic proximity Read ↗

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.Semantic proximity Read ↗

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.Semantic proximity Read ↗

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.Semantic proximity Read ↗

Clinical Features and Outcomes of Patients With Genotype 3 Hepatitis C Virus Infection in Korea: A Retrospective Observational Study.Semantic proximity Read ↗

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.Semantic proximity Read ↗

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.